Dantrolene sodium hemiheptahydrate (CAS 24868-20-0) is an orally active noncompetitive inhibitor of glutathione reductase demonstrating inhibitory activity with a Ki of approximately 111 6 M and an IC50 of around 52 3 M In addition dantrolene inhibits ryanodine receptor calcium channels RyR1 and RyR3 thereby reducing intracellular calcium release This compound is utilized in studies investigating the dysregulation of calcium homeostasis such as those related to stroke ischemia-reperfusion injury and neurodegenerative disorders It is also explored in the contexts of muscle spasticity malignant hyperthermia analgesia anti-inflammatory responses and detoxification